Skip to content

Magnesium Oxide and Vitamin C in Migraine

Comparison of the Effectiveness of Magnesium Oxide and Vitamin C Supplementation in Prevention of Migraine Headaches

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20201221049787N1
Enrollment
82
Registered
2021-01-16
Start date
2021-01-20
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Common Migraines. Condition 2: Classic Migraine. Migraine without aura Migraine with aura

Interventions

Intervention 1: Intervention group: Magnesium oxide tablets 250 mg once daily orally for 8 weeks. Intervention 2: Intervention group: Vitamin C 250 mg tablets once daily orally for 8 weeks.

Sponsors

Shahre-kord University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: According to ICHD-3 standards, the diagnosis of migraine should be made by a neurologist and they should be diagnosed with migraine at least one year before the visit Diagnosis of moderate to severe migraine (which is the number of headache attacks 2-15 times a month or attacks with less intensity and duration that cause the person to be unable to perform daily tasks

Exclusion criteria

Exclusion criteria: Fever or evidence of infection Simultaneous onset of other headaches such as tension headaches, sinusitis, or substance abuse headaches People with active peptic ulcer and severe gastrointestinal disorders, especially chronic diarrhea History of kidney failure History of diabetes history of major depression History of asthma and heart disease (conduction block and heart failure) Daily use of painkillers Pregnancy or pregnancy intent Having chronic diseases

Design outcomes

Primary

MeasureTime frame
The effect of migraine headaches on daily activities. Timepoint: At the beginning of the study and after eight weeks of medication. Method of measurement: MSQ questionnaire.;Depression score in Beck questionnaire. Timepoint: At the beginning of the study and after eight weeks of medication. Method of measurement: Beck Depression Inventory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSamira Sourani

Shahre-kord University of Medical Sciences

samira.sooraniii95@gmail.com+98 38 3336 4072

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026